학술논문
88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2023 20 Supplement
Subject
Language
ISSN
2590-0188